Intralipid ® attenuates acute cardiac allograft rejection in relation to promoting CD4 + CD25 + Foxp3 + regulatory T-cells and inhibiting toll-like receptor 4 expression
Transplantation Reports · 2017
DOI: 10.1016/j.tpr.2017.05.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Reports, 2017. Verfasst von Q. Ye und 6 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clinically available agents that promote the suppression of inflammatory processes with minimal adverse effects are highly desired. An FDA-approved nutrition supplement, Intralipid®, has shown its immunomodulatory potential. However, its influence on organ transplant rejection has not been tested. Here, we have investigated whether Intralipid® affect allograft outcome in a fully major histocompatibility complex (MHC)-mismatched rat model of heterotopic working-heart transplantation. Recipients were treated intravenously with Intralipid® (1.5 g/kg, clinical dosage) or saline (untreated control) on post-transplantation days (PODs) 1, 3, and 6. Treatment with Intralipid® results in a significant prolongation of median graft survival from 7 days to 12 days. On POD 7, while the allografts from our untreated (i.e., control) group exhibit severe rejection, the allografts from Intralipid®-treated group show milder rejection demonstrating preserved myocardium integrity and decreasing infiltration of inflammatory cells (ED1+ and CD3+ cells). Flow cytometry analysis reveals a marked increase of CD4+CD25+Foxp3+ regulatory T-cells (Tregs) in the peripheral blood of Intralipid®-treated recipients beginning on POD 3 (7.0% vs. 14.4%, untreated vs. Intralipid®-treated). Intralipid® treatment also promotes Tregs in the spleens and allograft hearts. Toll-like receptor 4 expression is markedly suppressed in the Intralipid®-treated allografts. Our results suggest a new use of Intralipid® to modulate immune responses in the setting of heart transplantation. This study could stimulate further mechanistic as well as treatment studies leading to the clinical application of Intralipid® as an adjunctive therapy with current immunosuppression agents to manage organ rejection.
Zitieren
APA
Ye, Q., Liu, L., Wu, Y., Yeh, F., Li, W., Tseng, L., & Ho, C. (2017). Intralipid ® attenuates acute cardiac allograft rejection in relation to promoting CD4 + CD25 + Foxp3 + regulatory T-cells and inhibiting toll-like receptor 4 expression. Transplantation Reports. https://doi.org/10.1016/j.tpr.2017.05.001
Vancouver
Ye Q, Liu L, Wu Y, Yeh F, Li W, Tseng L, et al. Intralipid ® attenuates acute cardiac allograft rejection in relation to promoting CD4 + CD25 + Foxp3 + regulatory T-cells and inhibiting toll-like receptor 4 expression. Transplantation Reports. 2017. doi:10.1016/j.tpr.2017.05.001
BibTeX
@article{Ye2017,
author = {Ye, Q. and Liu, L. and Wu, Y.L. and Yeh, F. and Li, W.F. and Tseng, L. and Ho, C.},
title = {Intralipid ® attenuates acute cardiac allograft rejection in relation to promoting CD4 + CD25 + Foxp3 + regulatory T-cells and inhibiting toll-like receptor 4 expression},
journal = {Transplantation Reports},
year = {2017},
doi = {10.1016/j.tpr.2017.05.001}
}
EUVIMED